Annexon, Inc. Stock Price, News & Analysis

On September 20, 2021, Annexon (Nasdaq: ANNX) announced its upcoming virtual C1q Series event scheduled for September 27, 2021, at 10:00 a.m. ET. This event will focus on the company's neurodegeneration franchise and will include presentations from the executive team and key opinion leaders. A live webcast will be accessible through the Investors section of annexonbio.com. Annexon specializes in developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders, leveraging its technology to target diseases caused by C1q activation.

Annexon (Nasdaq: ANNX) announced its second quarter 2021 financial results and business updates, highlighting progress in its autoimmune and neurodegenerative therapeutic franchises. The company advanced its clinical candidate ANX009 in treatment of autoimmune diseases and reported data from ANX005 trials in Huntington’s and Amyotrophic Lateral Sclerosis. Financially, Annexon reported a net loss of $31.3 million for Q2 2021, up from $12.2 million in Q2 2020, with R&D expenses rising to $24.6 million. The company appointed William D. Waddill to its Board, enhancing its strategic capabilities.

Annexon has announced advancements in its autoimmune pipeline, moving ANX009 into a Phase 1b program for Lupus Nephritis and expanding ANX005 to a Phase 2 trial for Multifocal Motor Neuropathy (MMN). ANX009 was well-tolerated in a Phase 1 trial and demonstrated robust C1q inhibition, leading to its selection for Lupus Nephritis patients. Meanwhile, ANX005 is expected to address unmet needs in MMN, which is characterized by progressive muscle weakness due to immune-mediated nerve damage. The company is poised to enhance its C1q inhibitor portfolio, targeting significant autoimmune conditions.

Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, will have its President & CEO, Douglas Love, present at the Raymond James Human Health Innovation Conference on June 23, 2021, at 1:20 pm EDT. The conference will focus on the company's pipeline of novel therapies targeting classical complement-mediated autoimmune and neurodegenerative disorders. Investors can access a live webcast under the 'Events & Presentations' section on the Investors page of www.annexonbio.com, with an archived replay available for 30 days.

Annexon reported its first-quarter 2021 financial results, highlighting key developments in its clinical pipeline. The Phase 2 trial of ANX005 for Huntington’s Disease is fully enrolled, with data expected in 2H 2021. Additionally, the first-in-human study of ANX009 has been completed, with results anticipated by summer 2021. The company is advancing drug candidates ANX105 and ANX1502, aiming for IND submissions by year-end 2021. As of March 31, 2021, Annexon holds $326.7 million in cash, sufficient to fund operations through 2023, despite a net loss of $26.0 million this quarter.

Annexon, Inc. (Nasdaq: ANNX) announced its participation in the Bank of America Securities 2021 Virtual Healthcare Conference on May 12, 2021, at 11:45 am EDT. Douglas Love, President & CEO, will present live at the event. Investors can access the live webcast through the ‘Events & Presentations’ section on Annexon's website, and a replay will be available for 30 days post-event. The company is focused on developing novel therapies for classical complement-mediated autoimmune and neurodegenerative disorders, utilizing a biomarker-driven strategy to enhance treatment efficacy.

Annexon, Inc. reported strong progress in its clinical pipeline during Q4 and full-year 2020. Their lead candidate, ANX005, showed positive results in a DDI study for Guillain-Barré Syndrome, with full C1q target engagement and improved patient outcomes. The company has a robust cash position of $351.2 million. However, R&D expenses surged to $49.3 million, and net losses increased to $63.4 million for the full year, up from $37.2 million in 2019.

Annexon (Nasdaq: ANNX) has initiated patient dosing in its Phase 2 ARCHER clinical trial to evaluate ANX007 for treating Geographic Atrophy (GA), a leading cause of blindness. Currently lacking approved treatments, GA affects over five million people globally. ANX007 aims to inhibit the classical complement pathway, potentially halting immune responses that damage retinal cells. The multicenter trial will assess the therapy's efficacy and safety in patients with GA, following promising Phase 1 results showing full C1q inhibition and good tolerance.

Annexon appoints Thomas G. Wiggans as Chairman

On February 8, 2021, Annexon (Nasdaq: ANNX) announced the appointment of Thomas G. Wiggans as its new Chairman. This change follows the retirement of William Young and Carol Gallagher from the board. The company also welcomed Dr. William H. Carson to the board, who has extensive experience in CNS disorders from his previous role as president and CEO at Otsuka Pharmaceutical. Both appointments aim to enhance Annexon's strategic direction as it advances its clinical-stage C1q inhibitors.